average dissociation constant determined from rate constants of association (k 1 The Ca 2+ influx via voltage-dependent Ca 2+ channels initiates and modulates cardiac and smooth muscle contraction (1) (2) (3) . Drugs that block these voltagedependent Ca 2+ channels are used for the treatment of various cardiovascular disorders and are referred to as Ca 2+ channel antagonists (4) (5) (6) (7) (8) . Nifedipine, nitrendipine, nisoldipine, and related 1,4-dihydropyridines are the most potent class of Ca 2+ channel antagonists, and radiolabeled dihydropyridines have been shown to bind with high affinity to membranes isolated from cardiac, skeletal, and smooth muscle (9) (10) (11) (12) (13) . To better understand the mechanism of action of the dihydropyridine Ca 2+ channel antagonists, investigators have undertaken the identification of the membrane receptor for these drugs in cardiac and skeletal muscle (14) (15) (16) , and the isolation and purification of the membrane receptor from enriched sources (i.e., transverse tubular membrane of skeletal muscle) (17) (18) (19) .
Considerable advances have been made in recent years in the structural and functional characterization of membrane receptors and ion channels using immunelogical probes (20) (21) (22) (23) (24) (25) (26) , Antibodies have been raised against membrane receptors or ion channels directly by immunization with purified membrane proteins, or indirectly by immunization with anti-ligand antibodies to produce anti-idiotypic antibodies. Anti-idiotypic antibodies have been very useful in studying receptor structure and function, as these antibodies bind to the ligand binding site on the receptor and in some cases can modify receptor function (21) . Anti-ligand antibodies (20, 21, 23, (26) (27) (28) (29) have been used to study structure-activity relationships between the ligand and antibody, and as specific molecules that can compete with the receptor for the ligand.
We report here the characterization of [ 3 H]nitrendipine binding properties of anti-dihydropyridine anti-bodies. High-affinity antibodies specific for the 1,4-dihydropyridine Ca 2+ channel blockers were produced using either a bovine serum albumin-dihydropyridine conjugate or a keyhole limpet hemocyanin-dihydropyridine conjugate. The protein-dihydropyridine conjugates were prepared using an affinity analog ofnifendipine -1,4-dihydro-2,6-dimethyl-4-(2-isothiocyanatophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester -which can react covalently with free ammo groups in both proteins to form a covalent dihydropyridineprotein conjugate. Anti-dihydropyridine antibodies have been found to bind [ 3 H]nitrendipine with high affinity and specificity. The dihydropyridine binding properties of the anti-dihydropyridine antibodies suggest that the antibodies resemble the membrane receptor for the 1,4-dihydropyridine Ca 2+ channel blockers with respect to affinity and specificity of 1,4-dihydropyridine binding.
METHODS

Preparation of dihydropyridine-protein conjugates
An affinity analog of nifedipine -1,4-dihydro-2,6-dimethyl-4-(2-isothiocyanatophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester (nifedipine-isothiocyanate) -was used to couple nifedipine covalently to various carrier proteins (i.e., bovine serum albumin, ovalbumin, and keyhole limpet hemocyanin) (see Fig. 1 ). The carrier protein (10 mg) was first dissolved in 10 ml of 100 mM sodium bicarbonate (pH 9.0) and then incubated with 0.6 mg of dihydropyridine-isothiocyanate (in ethanol) for 24 h at 37°C with shaking in the dark. The final concentration of nifedipine-isothiocyanate and ethanol in the incubation medium was 168 µM and 0.65%, respectively. Incorporation of nifedipine-isothiocyanate was monitored by including 
Immunization and antibody preparation
New Zealand white rabbits were first bled to obtain preimmune sera and then immunized intramuscularly and subcutaneously at multiple sites along the back and legs. Rabbits received 0.5 mg of nifedipine conjugate in Freund's complete adjuvant on day 0, followed by 0.5 mg insults in Freund's incomplete adjuvant every 2-3 weeks. The bovine serum albumin-nifedipine conjugate was used directly or cross-linked using 0.04% glutaraldehyde for 8 h at room temperature before immunization. In either case, the conjugate was emulsified in an equal volume of Freund's adjuvant. The keyhole limpet hemocyanin-nifedipine conjugate was mixed with an equal volume of aluminum hydroxide and phosphate-buffered saline (31), stirred for 1 h at 4°C, and then emulsified in an equal volume of Freund's adjuvant. Rabbits were bled after their third immunization every 2-3 weeks. Blood was withdrawn from the ear vein, allowed to clot overnight at 4°C, and serum was isolated following centrifugation. Either antisera were used directly or antibodies were partially purified from antisera by ammonium sulfate precipitation in the cold for 24 h. The precipitated immunoglobulin fraction was resuspended and desalted by passage through a Pharmacia PD-10 Sephadex G-25 column in the presence of phosphate-buffered saline at 4°C. 
Affinity and specificity of antidihydropyridine antibodies
A competitive radioimmunoassay was used to determine the specificity and affinity of the anti-dihydropyridine anti bodies. Average antibody dissociation constants, antibody specificity, and concentration of specific antibodies in the antiserum were calculated according to the methods of Muller (31 
Kinetics of [ 3 H]nitrendipine binding to anti-dihydropyridine antibodies
Association and dissociation kinetics of [ 3 H]nitrendipine binding to the antidihydropyridine antibodies were determined using antidihydropyridine antibodies bound to Protein-A Sepharose. An antibody-Protein-A Sepharose complex was formed by incubating the dihydropyridine-specific antisera (2.0ml) with Protein-A Sepharose (1.0ml) overnight at 4°C, followed by extensive washing in 150 mM NaCl, 10 mM TRIS (pH 7.2). Association kinetics were started by the addition of the antibody-Protein-A Sepharose complex to the assay mixture with 1.0 nM [ 3 H] nitrendipine. Aliquots were taken at different times and bound radioactivity was measured following centrifugation, as described previously. Nonspecific binding was measured in the presence of 1.0 µM. nitrendipine. Specific binding was calculated by subtraction of nonspecific binding from total binding. Dissociation kinetics were followed after 60 min of association, at which time the amount of specifically bound Dextran-coated charcoal was prepared by mixing 62.5 mg Dextran-70, 625 mg Norit A charcoal, and 100 ml 150 mM NaCl, 10 mM TRIS HCl, pH 7, 0.1% gelatin. The 4-chloro-l-naphthol, diethyl l,4-dihydro-2,4,6-trimethyl-3,5-pyridine-dicarboxylate, 3,5-diacetyl-l,4-dihydro-2,6-dimethylpyridine, 3,4-dimethoxybenzaidehyde, 2,6-lutidine, and 2,6-dimethylpiperidine were obtained from Aldrich. Protein-A Sepharose 4B was obtained from Pharmacia. All other reagents were of reagent grade quality. Protein was determined by the method of Lowry et al. (33) using the modification of Peterson (34) .
RESULTS
Preparation and characterization of dihydropyridine-protein conjugates
The nifedipine-protein conjugates were prepared using an affinity analog of nifedipine -1,4-dihydro-2,6-dimethyl-4-(2-isothiocyanatophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester (nifedipine-isothiocyanate) (14) . Incorporation of nifedipine-isothiocyanate into bovine serum albumin was monitored by including [ 3 H]nifedipine-isothiocyanate in the preparation of the bovine serum albumin-dihydropyridine conjugate. serum. The structure of the KLH-dihydropyridine conjugate is given in Fig. 1 .
[ 3 H]Nitrendipine binding properties of anti-dihydropyridine antibodies
The binding of free [ 3 H]nitrendipine (1.0 nM) to the antidihydropyridine antibodies in postimmune serum was tested using the Protein-A Sepharose immunoprecipitation technique. Figure 3 shows that in the presence of antiserum, the amount ofpHjnitrendipine bound to the antibody-Protein-A Sepharose complex was > 62,000 cpm or 62% of the total dihydropyridine antibodies in antisera, have been determined using a competitive radioimmunoassay, according to the method of Müller (31) . Before each competitive radioimmunoassay, a titer test was performed on each antiserum to determine the dilution required for 50% of the added [ 3 H]nitrendipine to be bound in the absence of unlabeled nitrendipine. Figure 5 shows the results of a titer test performed in the presence of 20 pM [ 3 H]nitrendipine. The titer for the various antisera produced ranged from 1:1000 to 1:145,000. Figure 6 shows the results of a typical competitive radioimmunoassay used for the determination of the affinity of anti-dihydropyridine antibodies for [ 3 H]nitrendipine and for the concentration of specific antidihydropyridine antibodies in the antiserum. The average apparent dissociation constant (K d ) of the [ 3 H]nitrendipine-antibody complex was 0.06 ± 0.02 nM for this antiserum, which was studied in detail. The average dissociation constant for all antisera produced ranged from 0.01 to 0.24 nM. Table 1 shows the average apparent dissociation constant and concentration of specific anti-dihydropyridine antibodies for antisera prepared from two rabbits and one sheep. An examination of antisera from the same animal immunized over several months has shown that the average dissociation constant did not change significantly, while the titer or specific antibody concentration increased with additional immunizations. a The average dissociation constant and concentration of specific anti-dihydropyridine antibodies were determined using a competitive radioimmunoassay, as described in the Experimental Procedures section.
Association and dissociation kinetics of
b Dissociation constants given are the average ± standard deviation for antiserum prepared from three different bleeds from the same animal. 
Specificity of anti-dihydropyridine antibodies
The specificity of the anti-dihydropyridine antibodies has been examined using various Ca 2+ channel modifiers and related compounds in the presence of 20 pM (Table 2) . Bay k 8644, a 1,4-dihydropyri- 
DISCUSSION
The production of antibodies, specific for the 1,4-dihydropyridine Ca 2+ channel antagonists, required the synthesis of an immunogenic dihydropyridine-protein conjugate. An affinity analog of nifedipine, nifedipine-isothiocyanate, has been used to prepare dihydropyridine-protein conjugates that have the essential moieties of nifedipine intact and available to the immune system. Preliminary labeling experiments in our laboratory with [
3 H]nifedipine-isothiocyanate have indicated that at high concentrations and high pH this analog was able to incorporate nonspecifically into several different proteins. Presumably, the nifedipine-isothiocyanate binds to low-affinity sites in these proteins and then reacts with a free amino group in the protein to form a covalent nifedipine-protein conjugate. We have optimized the conditions for the lowaffinity nifedipine-isothiocyanate labeling and used nifedipine-isothiocyanate to couple ~ 1 mol nifedipine covalently to 1 mol of carrier protein.
The ability of anti-dihydropyridine antibodies in antiSerum to bind free [
3 H]nitrendipine was demonstrated by the Protein-A Sepharose assay. This assay required only microliters of antiserum and had a very high signal to noise ratio. In addition, a positive result in this assay indicates that the [ 3 H]nitrendipine binding activity in antiserum is due to immunoglobulins that bind to Protein-A. The responses of 10 rabbits immunized with various dihydropyridine-protein conjugates were monitored using both the immunoblot assay and the Protein-A Sepharose assay. All 10 rabbits produced antidihydropyridine antibodies in a range of 10-12 weeks, and their production rose steadily over the initial 20-30 weeks. Detectable anti-dihydropyridine antibodies were present as early as 4 weeks after the initial immunization using keyhole limpet hemocyanin-nifedipine conjugates (see Fig. 1 ). The concentration of specific anti-dihydropyridine antibodies in antiserum was determined by the method of Müller (31), and ranged from 0.08 to 2.13mg/ml. Repeated immunization of the same animal over 1 year has been shown to increase the concentration of specific anti-dihydropyridine antibodies, while not significantly changing the dissociation constant of the antibodies for [
3 H]nitrendipine. The concentration of antibodies to the carrier protein was maintained at a relatively low level by changing the carrier protein in the dihydropyridine conjugate every several months.
The dihydropyridine binding properties of the antidihydropyridine antibodies, and the membrane receptor for the 1,4-dihydropyridine Ca 2+ channel blockers, have been compared with respect to affinity and specificity. To calculate the affinity and specificity of the anti-dihydropyridine antibodies for [ 3 H]nitrendipine, we have used a competitive radioimmunoassay according to the method of Müller (31) . Most methods for the determination of affinity constants cannot be applied to antibodies from serum because there is a heterogenous population of antibodies with different affinities. Mül-ler's method requires that the competitive radioimmunoassay be performed under equilibrium conditions, that the antibody concentrations be adjusted to 40-70% tracer binding in the absence of inhibitor, and that the separation technique must almost completely separate bound from free tracer. The competitive radioimmunoassay for [ 3 H]nitrendipine binding to anti-dihydropyridine antibodies that we have developed using dextran-coated charcoal meets all of the aforementioned requirements. The average dissociation constants of the [ 3 H]nitrendipine-antibody complex, determined using the competitive radioimmunoassay, ranged from 0.01 to 0.24 nM for all antisera studied, and are essentially in the same range as that measured for the membrane receptor for the 1,4-dihydropyridine Ca 2+ channel blockers (9-13). The average dissociation constant calculated from the kinetic data was 0.66 nAf, which is higher than that determined using the competitive radioimmunoassay, but still within the range of that measured for the membrane receptor. Thus, the anti-dihydropyridine antibodies, like the membrane receptor, have high affinity for [
3 H]nitrendipine. The high affinity of the anti-dihydropyridine antibodies also has been demonstrated by their ability to compete with the membrane receptor for [ The specificity of the anti-dihydropyridine antibodies, i.e., the cross-reactivity of antibodies with compounds structurally related to the hapten (nifedipine) used for immunization, has been examined using the competitive radioimmunoassay. In this assay, the competition of channel blockers or divalent cation chelation. It is evident from the data presented that the antidihydropyridine antibodies have a high affinity and specificity for the 1,4-dihydropyridine Ca 2+ channel blockers. The dihydropyridine binding characteristics of the anti-dihydropyridine antibodies compare favorably with the binding characteristics of the membrane receptor for the 1,4-dihydropyridines and suggest that these antibodies will be very useful in the production of anti-idiotypic antibodies to the dihydropyridine membrane receptor. The ability of the anti-dihydropyridine antibodies to recognize nifedipine, which is covalently attached to protein, suggests that these antibodies will be useful in the immunoprecipitation and immunolocalization of nifedipine-labeled receptors. Finally, because the anti-dihydropyridine antibodies bind the Ca 2+ channel antagonists with specificities and affinities similar to those of the membrane receptor, they will be very useful in the development of specific radioimmunoassays for the detection of 1,4-dihydropyridine Ca 2+ channel antagonists in human plasma.
